financetom
Business
financetom
/
Business
/
Ramkrishna Forgings receives board approval to raise up to Rs 1,000 crore via QIP
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ramkrishna Forgings receives board approval to raise up to Rs 1,000 crore via QIP
Oct 3, 2023 8:07 AM

Ramkrishna Forgings has received the necessary board approvals to raise up to Rs 1,000 crore through a qualified institutional placement (QIP), the company's Managing Director Naresh Jalan said Tuesday.

Share Market Live

NSE

In an interview with CNBC-TV18, Jalan said, "...a lot of consolidation is happening in the forging industry. So, we feel that there are a lot of opportunities which we are facing and if there is a right opportunity and right segment where we can spend money – that is the reason we have taken this enabling regulation.”

The total number of securities proposed to be issued through QIP “shall be determined after fixation of issue price" at the time of issuance of securities, the company said in a filing with the stock exchanges.

The company has also received board approval for the conversion of 46 lakh warrants into equity shares. This will be on receipt of an amount totaling Rs 70.72 crore. After the issue of these equity shares, the capital of the company increased to Rs 32.9 crore, consisting of 16.44 crore fully paid-up equity shares.

Ramkrishna Forgings is into rolled, forged, and machined goods. In August, the company secured an order valued at approximately Rs 74 crore (equivalent to 8.25 million Euros) from a well-known European OEM (original equipment manufacturer) and tier-1 supplier. Under the terms of the agreement, Ramkrishna Forgings will provide front and rear axle components for a duration of five years, per their stock exchange filing.

Jalan also pointed out that the company is scaling up on auto operations exceptionally well and that the Titagarh Rail joint venture (JV) will be in place by the first half of 2026.

The company's stock has witnessed a remarkable surge of over 214 percent in the past year.

For more details, watch the accompanying video

Also, catch all the updates on markets with CNBC-TV18.com's blog

(Edited by : Shweta Mungre)

First Published:Oct 3, 2023 5:07 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Stallion Uranium Signs Letter of Intent for Horse Heaven Gold and Antimony Project
Stallion Uranium Signs Letter of Intent for Horse Heaven Gold and Antimony Project
Oct 9, 2024
07:50 AM EDT, 10/09/2024 (MT Newswires) -- Stallion Uranium ( STLNF ) on Wednesday said it has entered into a binding letter of intent to grant an 80% interest in its Horse Heaven Gold and Antimony project to an arm's-length party for staged payments of $600,000 cash and $1.1 million worth of optionor shares. The optionor must also complete $5...
More airlines fly over Afghanistan in last week as Middle East tensions rise
More airlines fly over Afghanistan in last week as Middle East tensions rise
Oct 9, 2024
LONDON/KABUL (Reuters) - Airlines have diverted more flights over Afghanistan over the past week to avoid Iranian airspace, data shows, adding to journey times and fuel costs in the latest disruption for routes between Asia and Europe as tensions in the Middle East escalate. Flights over Afghanistan were already growing in recent months, but expectations of an Israeli response to...
Can-Fite BioPharma Says Its Pancreatic Cancer Drug Candidate Receives US FDA Orphan Drug Designation
Can-Fite BioPharma Says Its Pancreatic Cancer Drug Candidate Receives US FDA Orphan Drug Designation
Oct 9, 2024
07:51 AM EDT, 10/09/2024 (MT Newswires) -- Can-Fite BioPharma ( CANF ) said Wednesday that its oncology drug candidate Namodenoson, whihc treats pancreatic cancer, has received Orphan Drug Designation from the US Food and Drug Administration. The company said it is now finalizing all preparatory requirements for a mid-stage trial in participants suffering from pancreatic cancer to evaluate the safety,...
Novavax Secures EU Marketing Authorization for Updated Nuvaxovid COVID-19 Vaccine
Novavax Secures EU Marketing Authorization for Updated Nuvaxovid COVID-19 Vaccine
Oct 9, 2024
07:33 AM EDT, 10/09/2024 (MT Newswires) -- Novavax ( NVAX ) said Wednesday that the European Commission granted the marketing authorization for its updated Nuvaxovid COVID-19 vaccine for use in individuals of at least 12 years old. The company said the approval was based on non-clinical data that showed Nuvaxovid's cross-reactivity across several JN.1 lineage viruses. Novavax ( NVAX )...
Copyright 2023-2026 - www.financetom.com All Rights Reserved